These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 35430971)
1. Translocator Protein 18-kDa: A Promising Target to Treat Neuroinflammation- related Degenerative Diseases. Tremolanti C; Germelli L; Barresi E; Da Pozzo E; Simorini F; Castellano S; Taliani S; Da Settimo F; Martini C; Costa B Curr Med Chem; 2022 Aug; 29(28):4831-4861. PubMed ID: 35430971 [TBL] [Abstract][Full Text] [Related]
2. The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog. Filiou MD; Banati RB; Graeber MB CNS Neurol Disord Drug Targets; 2017; 16(9):990-999. PubMed ID: 28982340 [TBL] [Abstract][Full Text] [Related]
3. The translocator protein (18kDa) and its role in neuropsychiatric disorders. Barichello T; Simões LR; Collodel A; Giridharan VV; Dal-Pizzol F; Macedo D; Quevedo J Neurosci Biobehav Rev; 2017 Dec; 83():183-199. PubMed ID: 29054730 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. Vicente-Rodríguez M; Mancuso R; Peris-Yague A; Simmons C; ; Gómez-Nicola D; Perry VH; Turkheimer F; Lovestone S; Parker CA; Cash D J Neuroinflammation; 2023 Apr; 20(1):92. PubMed ID: 37032328 [TBL] [Abstract][Full Text] [Related]
5. Translocator protein (18 kDa) (Tspo) in the retina and implications for ocular diseases. Hector M; Langmann T; Wolf A Prog Retin Eye Res; 2024 May; 100():101249. PubMed ID: 38430990 [TBL] [Abstract][Full Text] [Related]
6. Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Da Pozzo E; Giacomelli C; Barresi E; Costa B; Taliani S; Passetti Fda S; Martini C Biochem Soc Trans; 2015 Aug; 43(4):559-65. PubMed ID: 26551693 [TBL] [Abstract][Full Text] [Related]
7. Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. Narayanaswami V; Dahl K; Bernard-Gauthier V; Josephson L; Cumming P; Vasdev N Mol Imaging; 2018; 17():1536012118792317. PubMed ID: 30203712 [TBL] [Abstract][Full Text] [Related]
8. Neuroinflammation and psychiatric disorders: Relevance of C1q, translocator protein (18 kDa) (TSPO), and neurosteroids. Rupprecht R; Rupprecht C; Di Benedetto B; Rammes G World J Biol Psychiatry; 2022; 23(4):257-263. PubMed ID: 34320915 [TBL] [Abstract][Full Text] [Related]
10. Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization. Guilarte TR; Rodichkin AN; McGlothan JL; Acanda De La Rocha AM; Azzam DJ Pharmacol Ther; 2022 Jun; 234():108048. PubMed ID: 34848203 [TBL] [Abstract][Full Text] [Related]
11. Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. Kreisl WC; Henter ID; Innis RB Adv Pharmacol; 2018; 82():163-185. PubMed ID: 29413519 [TBL] [Abstract][Full Text] [Related]
12. Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands. Taliani S; Pugliesi I; Da Settimo F Curr Top Med Chem; 2011; 11(7):860-86. PubMed ID: 21291396 [TBL] [Abstract][Full Text] [Related]
13. Acetamidobenzoxazolone scaffold as a promising translocator protein (18 kDa, TSPO) marker for neuroinflammation imaging: Advancement in last decennial period. Adhikari A; Zhang MR; Tiwari AK Drug Dev Res; 2022 Nov; 83(7):1519-1533. PubMed ID: 36074736 [TBL] [Abstract][Full Text] [Related]
14. Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. Werry EL; Bright FM; Piguet O; Ittner LM; Halliday GM; Hodges JR; Kiernan MC; Loy CT; Kril JJ; Kassiou M Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261683 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases. Arbo BD; Benetti F; Garcia-Segura LM; Ribeiro MF J Steroid Biochem Mol Biol; 2015 Nov; 154():68-74. PubMed ID: 26200949 [TBL] [Abstract][Full Text] [Related]
16. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2). Kim T; Pae AN Expert Opin Ther Pat; 2016 Nov; 26(11):1353-1366. PubMed ID: 27599163 [TBL] [Abstract][Full Text] [Related]
17. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1). Kim T; Pae AN Expert Opin Ther Pat; 2016 Nov; 26(11):1325-1351. PubMed ID: 27607364 [TBL] [Abstract][Full Text] [Related]
18. Translocator protein (TSPO): the new story of the old protein in neuroinflammation. Lee Y; Park Y; Nam H; Lee JW; Yu SW BMB Rep; 2020 Jan; 53(1):20-27. PubMed ID: 31818362 [TBL] [Abstract][Full Text] [Related]
19. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Guilarte TR Pharmacol Ther; 2019 Feb; 194():44-58. PubMed ID: 30189290 [TBL] [Abstract][Full Text] [Related]
20. Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Beckers L; Ory D; Geric I; Declercq L; Koole M; Kassiou M; Bormans G; Baes M Mol Imaging Biol; 2018 Feb; 20(1):94-102. PubMed ID: 28695372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]